Ribavirin has been shown to have broad-spectrum antiviral activity. To study its tissue distribution and disappearance rate, a single dose of 10 mg/kg which contained 10 ,uCi of ['4C]ribavirin was injected intravenously into rhesus monkeys and intramuscularly into monkeys and rats. Except for peak plasma concentrations and the initial phases of the plasma disappearance and urine excretion curves, no significant difference was observed between plasma, tissue, or urine values for intramuscularly or intravenously injected monkeys. Plasma disappearance curves were triphasic; plasma concentrations of ribavirin were similar for both monkeys and rats. Rats excreted ribavirin in the urine more rapidly and to a greater extent (82% excreted in 24 h) than did monkeys (60% excreted in 72 h). In the rat, only 3% of the injected ['40]ribavirin was detected in expired C02. Therefore, for both species, urine was the major route for the elimination of labeled ribavirin and its metabolites from the body. In monkeys, the amount of parent drug in blood cells increased through 48 h and remained stable for 72 h, whereas in rats, ribavirin decreased at a rate similar to the plasma disappearance curve. Concentrations of ribavirin at 8 h were consistently higher in monkeys than in rats for all tissues except the brain. Thus, these differences in blood cellular components and organ content and in urine excretion suggested that there was greater tissue retention of ribavirin in monkeys than in rats.
Ribavirin has been shown to have broad-spectrum antiviral activity. To study its tissue distribution and disappearance rate, a single dose of 10 mg/kg which contained 10 ,uCi of ['4C]ribavirin was injected intravenously into rhesus monkeys and intramuscularly into monkeys and rats. Except for peak plasma concentrations and the initial phases of the plasma disappearance and urine excretion curves, no significant difference was observed between plasma, tissue, or urine values for intramuscularly or intravenously injected monkeys. Plasma disappearance curves were triphasic; plasma concentrations of ribavirin were similar for both monkeys and rats. Rats excreted ribavirin in the urine more rapidly and to a greater extent (82% excreted in 24 h) than did monkeys (60% excreted in 72 h). In the rat, only 3% of the injected ['40 ]ribavirin was detected in expired C02. Therefore, for both species, urine was the major route for the elimination of labeled ribavirin and its metabolites from the body. In monkeys, the amount of parent drug in blood cells increased through 48 h and remained stable for 72 h, whereas in rats, ribavirin decreased at a rate similar to the plasma disappearance curve. Concentrations of ribavirin at 8 h were consistently higher in monkeys than in rats for all tissues except the brain. Thus, these differences in blood cellular components and organ content and in urine excretion suggested that there was greater tissue retention of ribavirin in monkeys than in rats. Ribavirin (1-,B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a water-soluble synthetic nucleoside with broad-spectrum antiviral properties (8, 12) . Previous studies with intravenous (i.v.) or oral dosing of tritium-labeled ribavirin in rats have suggested that this drug was rapidly lost from all tissues of the body (7, 17) . Based on these observations, multiple-dose schedules have been utilized to test the efficacy of ribavirin therapy in humans and in rhesus and squirrel monkeys (2, 4, 6, 9, 15, 18) . Since the tritium label was in both the triazole ring and ribose components of ribavirin, its disappearance after injection into rats may not reflect the true tissue uptake and retention of the drug. Therefore, the studies have been repeated in rats to measure tissue distribution and disappearance rates of ribavirin labeled with 14C in the 3 position of the triazole ring. Since there is little evidence for in vivo degradation of the triazole ring (7), the radioactivity measured in tissues represents at Recent observations have suggested that ribavirin therapy is an effective antiviral drug for the treatment of several viral infections ofrhesus and squirrel monkeys (4, 9, 14, 15) . Therefore, disappearance rates and tissue distribution following a single dose of "C-labeled ribavirin were measured in rhesus monkeys to determine whether there were differences in the way these monkeys and rats metabolized this drug. Since the previous monkey studies on the efficacy of ribavirin had utilized intramuscular (i.m.) injections of ribavirin, this route of administration was compared with i.v. injection to determine whether the route of administration had any effect on tissue distribution and disappearance of the drug.
MATERIALS AND METHODS Drug used and dosage. Ribavirin and "C-labeled VOL. 19,1981 RIBAVIRIN DIST] with a concentration of 67 mg/ml. Unlabeled ribavirin was dissolved in sterile distilled water and combined with '4C-ribavirin to make a stock solution at a concentration of 100 mg/ml with a '"C radioactivity of 100 guCi/ml. This solution was used as prepared for a single i.m. or i.v. dose of 10 mg of ribavirin per kg in monkeys. The solution was diluted 10-fold with sterile distilled water to a 10 mg/ml (10 jzCi/ml) solution for a single i.m. dose of 10 mg/kg in rats. Preliminary data indicated that i.m. injection of 100 or 10 mg/ml solution in rats gave similar results; therefore, the more dilute solution was utilized because of the more accurate administration of the larger fluid volume.
Animals. Forty-eight male, albino Sprague-Dawley rats (Flow Laboratories, Dublin, Va.) weighing 250 to 390 g were utilized. They were housed in individual cages and provided water ad libitum. All rats were injected i.m. with 10 mg of [f4C]ribavirin per kg, and 6 rats each were killed at 0.5, 1, 2, 4, 8, 24, 48, and 72 h post-inoculation. All but the 8-and 72-h groups were placed in individual stainlesg steel metabolic cages with a funnel for quantitative collections of urine. At each time period, complete urine collections were obtained on individual rats, which included distilled water wash of the cage, collected urine, and residual fluid in the bladder. Total volumes and wash were measured and samples saved for determination of 14C content.
The 8-and 72-h groups of rats were placed in individual, closed-circuit glss metabolism cages that allowed complete collection ofurine, feces, and expired C02 (20) were placed in six monkeys for the purpose of i.v. injections. Foley urethral catheters were placed in female monkeys for urine collection. An adhesive pediatric urine collection bag was applied to male monkeys. Monkeys were replaced in restraint chairs and were kept in these chairs for the duration of the experiment. Vascular catheters were infused with heparinized saline (10 U/ml) at a total rate of 6 ml/h. One day after surgery, the monkeys were injected with radioactive ribavirin, after which they were fasted for 24 h and provided water ad libitum for the remainder of the experiment. Radioactivity determinations. A 0.1-ml sample of plasma or urine was added to an aqueous liquid scintillation system. Whole blood (0.5 ml), KOH extracts (0.5 ml), and tissue samples were (Table 3 ). The monkeys continued to excrete ribavirin in urine at a slow rate so that by 72 h, less than 60% of the injected dose was in the urine (Table 3) . As with rats, the urine excretion can be described as a biphasic curve which has two components ( (Table  2) . In rats injected with labeled ribavirin, the drug disappeared rapidly from the plasma (Table 1). Ribavirin also disappeared from the cellular components of the blood, but initially at a slightly slower rate than from plasma. By 8 h, the disappearance from the blood cells paralleled that observed for plasma. Least-square analysis of the curves for disappearance of ribavirin from the plasma, revealed three major components through 72 h ( Table 4 ). The first 9 and 5%, respectively, of the injected drug. In the i.m. treated monkeys, cellular components of the blood at 34 and 43 days postinjection contained 2 and 1%, respectively, of the injected ribavirin. Thus, in monkeys, the cellular components of blood contained 17 and 200 times more ribavirin than did blood cells from rats taken 8 and 72 h, respectively, postinjection.
As noted in rats, disappearance of ribavirin from plasma in monkeys contained three major components (Table 4 ). The disappearance rate (K) for the first phase of the curve was significantly faster for the i.v. injected group compared with that for the i.m. treated monkeys or rats, which can probably be explained by slower absorption by the latter route. Further, the disappearance rate of the first phase of the curve was slower in i.m. treated monkeys than in similarly treated rats, which probably represents differences in absorption and elimination rates in these two species.
The first, second, and third phases of each plasma curve contained, respectively, 6, (Table 3) . As with rats, skeletal muscle contained the largest amount of total body ribavirin of the tissues analyzed (Table 5 ). This was followed by cellular components of blood, which contained 14% of the ribavirin, and liver, which contained as much as 8% of the total residue. At 5 to 6 weeks postinjection, the liver still contained almost 0.1% of the injected ribavirin. Preliminary data on the acid-soluble extract of blood cells and liver with solvent system of Miller et al. (7) indicated that the ribavirin was equally distributed between the parent drug and its phosphorylated ribonucleotides. Further, by measurement of chloride space (5), it was determined that blood in liver samples accounted for only 2 to 3% of the ribavirin present in the tissue.
At 8 h postinjection, the brain accounted for (Table 6) . If the data are listed in descending order of concentration of drug per gram of tissue, the highest concentration differentials were found in blood cells, liver, kidney, adrenal gland of monkeys as compared with rats. In contrast, only twofold elevations in concentrations were found in the spleen, heart, and lung. In both species, the brain had the lowest concentration of radioactivity of tissues studied. DISCUSSION The data in this paper are expressed as concentration of parent drug equivalents, which is based on measurement of radioactivity in tissue or biological fluid. It must be remembered also that all of the radioactivity that is measured does not represent ribavirin. It has been shown that in orally dosed rats, 50 to 60% of the radioactivity in the liver, kidney, and spleen at 48 h postinjection represents the original ribavirin, whereas the remainder ofthe organ radioactivity is comprised of various phosphorylated metabolites of ribavirin (7) . In rat lungs, ribavirin represented an even smaller percentage of the total lung radioactivity (7) . Similarly, preliminary data from liver and blood cells of monkeys suggest that the ribavirin was equally distributed between the parent drug and its phosphorylated ribonucleotides. However, it has been shown that most of the phosphorylated metabolites of ribavirin also demonstrate significant antiviral activity (16) . Future work will be designed to study the distribution of these metabolites in various tissues after an injection of (7, 17) , reveals that the initial absorption, distribution, and excretion of ribavirin were slightly slower in orally dosed rats. By 24 h, however, the percentage of administered radioactivity in the urine and in certain tissues was similar for the two studies. With either 3H-or 14C-labeled ribavirin, the drug was rapidly lost from tissues and extracellular fluids of the rat. In the study with the orally administered drug, the rats received 38 mg of ribavirin per kg, whereas in the present study with i.m. injection, the dose was 10 mg/ kg. It is unlikely that the differences in the uptake and excretion were due to a discrepancy in the administered dose, since variations in oral dosage did not appreciably affect excretion rates (17) . Recently, similar rates of recovery of ribavirin were observed in rats injected intravenously with [14C]ribavirin (1) .
In comparison with rats, tissues of the rhesus monkey retained considerably more ribavirin and its metabolites, as measured by decreased amount of drug in the urine and in higher tissue concentrations at 8 h after injection of [ It can be concluded that except for the initial 1047 VOL. 19, 1981 on November 2, 2017 by guest http://aac.asm.org/ Downloaded from phase of the plasma disappearance curve and urinary excretion curve, there was no significant difference between any of the plasma, whole blood, blood cell, tissue, or urinary parameters of the monkeys injected i.v.or i.m. with ribavirin. Because of the rapid absorption of ribavirin by the latter route, there probably would be no particular advantage to periodic i.v. dosing.
If the concentration of ribavirin is expressed as micrograms per gram, only the blood cells, liver, and kidney had cellular concentrations in excess of 10 ,tg/g. In most in vitro systems, the effective concentration of ribavirin appears to be between 10 and 25 ,g/ml of tissue culture maintenance medium (10, 11, 15) . Thus, with a 10 mg/kg dose, only a few of the organs appear to have adequate antiviral concentrations at 8 h postinjection. However, most of these studies have not measured the intracellular concentration or distribution of ribavirin and its phosphorylated metabolites. Knowledge of this type of intracellular distribution and most effective antiviral metabolite will be required to develop an effective dosing schedule.
Initial multiple dosing could rapidly increase the ribavirin content of tissues, such as liver, to concentrations that would have significant antiviral activity. It is interesting to note that some of the effects of ribavirin in increasing survival or delaying death in rhesus monkeys experimentally infected with Lassa virus have been shown to occur concurrently with reduction in liver pathology (4) . The half-life of this drug in the cells of rhesus monkeys appears to be much longer than that in cells of rats. Since ribavirin is not virucidal (12) , maintenance of effective tissue concentrations is probably required until the development of host immune mechanisms. Dosage beyond this time may be hazardous, since tissue accumulation may be expected to occur with chronic administration.
In contrast to the cellular components of blood and liver, there was only a slight accumulation of ribavirin in the brain of rats or monkeys. This would suggest that ribavirin is able only slowly to cross the blood-brain barrier. Thus, the inability of ribavirin to accumulate in the brain may explain the lack of effect of systemic ribavirin treatment against diseases where latent neurological symptoms are related to viral encephalitis (13) and to acute viral infections with primary encephalitis as the principal component (15) .
